pharma · Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis (NASH) Cirrhosis · MDGL
Madrigal Pharmaceuticals EU
Madrigal Pharmaceuticals EU Limited
Madrigal Pharmaceuticals EU is a pharma organization headquartered in Conshohocken, USA. It trades on NYSE under ticker MDGL. Primary therapeutic focus areas include Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steat
200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US HQ
2016 Founded
1,071 Employees
Public company Type
MDGL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
- Founded
- 2016
- Employees
- 1,071
- Programs
- 16
- Drugs
- 11
- Patents
- 26
MGL-3196 (resmetirom)
Phase 2 · small molecule · Heterozygous Familial Hypercholesterolemia
MGL-3196 (resmetirom) for Heterozygous Familial Hypercholesterolemia is a Phase 2 program (small_molecule) at Madrigal Pharmaceuticals EU Limited with 1 ClinicalTrials.gov record(s).
Internal code MGL-3196-06
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Madrigal Pharmaceuticals EU Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Heterozygous Familial Hypercholesterolemia
- Status
- completed
- Trials
- 1